Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY3410738 in Advanced Solid Tumors with IDH1/2 Mutations
jRCT2031200178Phase 1Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of crelosidenib in cholangiocarcinoma (CCA), chondrosarcoma, glioma and 1 more (3 arms), sponsored by Loxo Oncology. Primary endpoint: Recommended Phase 2 dose of LY3410738 monotherapy. Started Dec 2020; status: active, not recruiting.
02
Drugs
crelosidenib
03
Conditions
cholangiocarcinoma (CCA)chondrosarcomagliomaNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200178.